Journal article

Clinical recommendations for the use of lapatinib ditosylate plus capecitabine for patients with advanced or metastatic HER2-positive breast cancer

Raymond D Snyder, Frances M Boyle, Arlene Chan, Paul S Craft, Richard De Boer, Paul N Mainwaring, Nicole J McCarthy, Nicholas R Wilcken

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | WILEY | Published : 2009

Abstract

Primary and acquired resistance to trastuzumab pose a therapeutic challenge when treating patients with HER2 (erbB-2)-positive locally advanced or metastatic breast cancer (MBC). The recent introduction of lapatinib (Tykerb/Tyverb, GlaxoSmithKline, Brentford, UK) provides a new management option for such patients. A prospective, randomized phase III clinical trial has confirmed that lapatinib in combination with capecitabine extends time to progressive disease in HER2-positive MBC, compared with capecitabine alone in patients with disease progression despite prior anthracycline, taxane and trastuzumab therapy. Preliminary data also indicate that lapatinib may exert a beneficial effect on bra..

View full abstract

University of Melbourne Researchers